SHANGHAI FOSUN PHARMACEUTICAL (GROUP) CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 22.73 CNY | -0.09% |
|
-0.22% | -9.19% |
| Sales 2024 * | 45.05B 6.22B | Sales 2025 * | 50.8B 7.01B | Capitalization | 54.25B 7.49B |
|---|---|---|---|---|---|
| Net income 2024 * | 3.34B 461M | Net income 2025 * | 4.28B 590M | EV / Sales 2024 * | 1.55 x |
| Net Debt 2024 * | 15.69B 2.17B | Net Debt 2025 * | 17.77B 2.45B | EV / Sales 2025 * | 1.42 x |
| P/E ratio 2024 * |
18
x | P/E ratio 2025 * |
14
x | Employees | 40,370 |
| Yield 2024 * |
1.84% | Yield 2025 * |
2.15% | Free-Float | 63.42% |
More Fundamentals
* Assessed data
More news
More press releases
More news
| 1 day | -0.09% | ||
| 1 week | -0.22% | ||
| Current month | -1.47% | ||
| 1 month | -5.68% | ||
| 3 months | +0.04% | ||
| 6 months | -16.31% | ||
| Current year | -9.19% |
1 week
22.45
22.88
1 month
22.2523.68
Current year
20.3825.89
1 year
20.3832.74
3 years
20.3891.69
5 years
20.3891.69
10 years
16.5091.69
| Managers | Title | Age | Since |
|---|---|---|---|
De Yong Wen
CEO | Chief Executive Officer | 52 | - |
Dong Ming Li
PSD | President | 55 | 20-10-28 |
Yi Fang Wu
CHM | Chairman | 54 | 04-03-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Fang Yao
BRD | Director/Board Member | 54 | 10-04-08 |
Qi Yu Chen
BRD | Director/Board Member | 52 | 94-03-31 |
Xiao Hui Guan
BRD | Director/Board Member | 53 | - |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 1.27% | 2 M€ | -19.10% | - | |
| 1.18% | 4 M€ | -2.96% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-24 | 22.73 | -0.09% | 5,584,819 |
| 24-04-23 | 22.75 | +0.04% | 7,525,549 |
| 24-04-22 | 22.74 | +1.02% | 6,167,673 |
| 24-04-19 | 22.51 | -1.14% | 5,892,389 |
| 24-04-18 | 22.77 | -0.04% | 8,818,726 |
End-of-day quote Shanghai S.E., April 23, 2024
More quotes
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. is a pharmaceutical group organized around 4 areas of activities:
- research, development and manufacturing of medicines (72.1% of net sales): for the treatment of cardiovascular diseases, digestive tract, metabolism, central nervous system and blood system disorders, and infectious diseases;
- sale of medical equipments and diagnosis products (17.3%);
- medical and hospital services (10.5%);
- other (0.1%).
China accounts for 72.9% of net sales.
Sector
Pharmaceuticals
Calendar
2024-04-28
- Q1 2024 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
A
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
8
Last Close Price
22.73
CNY
Average target price
29.75
CNY
Spread / Average Target
+30.88%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -9.19% | 7.49B | |
| +25.61% | 660B | |
| +23.22% | 562B | |
| -5.24% | 358B | |
| +16.49% | 322B | |
| +8.28% | 297B | |
| +13.27% | 219B | |
| -9.65% | 196B | |
| +6.68% | 199B | |
| -8.75% | 149B |
- Stock Market
- Equities
- 600196 Stock
